Intranasal Brain Cancer Treatment – NeOnc Technologies is revolutionizing brain cancer treatment
Investors and biotech innovators, discover how NeOnc Technologies is revolutionizing brain cancer treatment with intranasal drug delivery that bypasses the blood-brain barrier. Janet Alvarez interviews Amir F. Heshmatpour, Executive Chairman and President of NeOnc, to discuss:
A groundbreaking delivery method for brain cancer drugs via the nose
Phase 1 and Phase 2 clinical trials currently underway across 10+ hospitals
Expansion into India and the Middle East, including a $50M Quasar partnership
Inclusion in the Russell 2000 and recent Nasdaq listing
Vision for FDA-approved standard-of-care cancer treatments within 3–5 years
With 179 patents and cutting-edge acquisitions in AI, quantum modeling, and 3D printing, NeOnc is positioning itself as a major player in oncology innovation.
➡️ Learn why NeOnc (Nasdaq: NENC) may be undervalued and how it’s disrupting the biotech space.
📺 Watch now for exclusive insights from the frontlines of cancer research and investment strategy.
📌 Tags
#Biotech #BrainCancer #NasdaqStocks #NeOnc #IntranasalTherapy #NewToTheStreet #CancerResearch #PharmaInnovation #HealthcareInvesting #Russell2000 #Oncology #FDAApproval #BiotechStocks #ClinicalTrials #AIinHealthcare #USCResearch #Neuroscience #InvestInBiotech #StartupStocks
